Iovance Biotherapeutics
IOVA
HK$13.73
Share price
0.00%
Change (1 day)
-76.20%
Change (1 year)
Categories
Iovance Biotherapeutics (IOVA) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : HK$1.56 Billion
According to Iovance Biotherapeutics 's latest financial reports the company's total liabilities are HK$1.56 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Iovance Biotherapeutics - Total liabilities on balance sheet (from 2008 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | HK$1.55 B | 1.58% |
| 2023-12-31 | HK$1.52 B | 19.05% |
| 2022-12-31 | HK$1.28 B | 5.78% |
| 2021-12-31 | HK$1.21 B | 39.86% |
| 2020-12-31 | HK$0.86 B | 143.94% |
| 2019-12-31 | HK$0.35 B | 210.6% |
| 2018-12-31 | HK$0.11 B | 48.22% |
| 2017-12-31 | HK$77.28 M | 100.61% |
| 2016-12-31 | HK$38.52 M | 204.94% |
| 2015-12-31 | HK$12.63 M | -2% |
| 2014-12-31 | HK$12.89 M | -26.76% |
| 2013-12-31 | HK$17.6 M | -79.99% |
| 2012-12-31 | HK$87.96 M | -15.16% |
| 2011-12-31 | HK$0.10 B | 1519.11% |
| 2010-12-31 | HK$6.4 M | 3472.2% |
| 2009-12-31 | HK$0.17 M | 597.07% |
| 2008-12-31 | HK$0.02 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 NRC Health
NRC | HK$0.82 B | -46.95% | 🇺🇸 USA |
 Nymox Pharmaceutical NYMX | HK$24.7 M | -98.42% | Bahamas |